Viking Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Viking Therapeutics (VKTX) Briefly Falls to Low
November 8, 2018 10:41 AM ESTViking Therapeutics (NASDAQ: VKTX) Briefly Falls to Low
... MoreViking Therapeutics (VKTX) Tops Q3 EPS by 1c
November 7, 2018 4:53 PM ESTViking Therapeutics (NASDAQ: VKTX) reported Q3 EPS of ($0.11), $0.01 better than the analyst estimate of ($0.12).
"The third quarter was an exciting period for Viking as we made several important announcements regarding our pipeline programs," stated Brian Lian, Ph.D., chief executive officer of Viking Therapeutics. "With our VK2809 program for NASH, we announced topline data from a Phase 2 trial in patients with NAFLD and... More
